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959Mechanisms of Atherothrombosis and Vascular
Response to Primary Percutaneous Coronary
Intervention in Women Versus Men With
Acute Myocardial Infarction
Results of the OCTAVIA StudyABSTRACTFro
Un
Ita
Sa
Po
Os
Ca
Un
Oh
Sa
wi
do
Ju
Me
Th
St.
LifOBJECTIVES This study sought to assess in vivo sex differences in the pathophysiology of ST-segment elevation
myocardial infarction (STEMI) and vascular response to primary percutaneous coronary intervention (PCI).
BACKGROUND There is no consensus on whether differences in the pathophysiology of STEMI and response to primary
PCI between women and men reﬂect biological factors as opposed to differences in age.
METHODS In this prospective, multicenter study, 140 age-matched men and women with STEMI undergoing primary
PCI with everolimus-eluting stent were investigated with intravascular optical coherence tomography, histopathology-
immunohistochemistry of thrombus aspirates, and serum biomarkers. Primary endpoints were the percentages of culprit
plaque rupture at baseline and everolimus-eluting stent strut coverage at 9-month follow-up as determined by optical
coherence tomography.
RESULTS Men and women had similar rates of plaque rupture (50.0% vs. 48.4%; risk ratio [RR]: 1.03; 95% conﬁdence
interval [CI]: 0.73 to 1.47; p ¼ 0.56). Nonruptured/eroded plaques comprised 25% of all cases (p ¼ 0.86 in men vs.
women). There were no sex differences in composition of aspirated thrombus and immune and inﬂammatory serum
biomarkers. At 9 months, women had similar strut coverage (90.9% vs. 92.5%; difference in medians: RR: 0.2%; 95% CI:
–0.4% to 1.3%; p ¼ 0.89) and amount of in-stent neointimal obstruction (10.3% vs. 10.6%; p ¼ 0.76) as men did. There
were no sex differences in clinical outcome either at 30-day or 1-year follow-up.
CONCLUSIONS In patients presenting with STEMI undergoing primary PCI, no differences in culprit plaque morphology
and factors associated with coronary thrombosis were observed between age-matched men and women. Women also
showed similar vascular healing response to everolimus-eluting stents as men did. (Optical Coherence Tomography
Assessment of Gender Diversity In Primary Angioplasty: The OCTAVIA Trial [OCTAVIA]; NCT01377207) (J Am Coll Cardiol
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CI = conﬁdence interval
EES = everolimus-eluting
stent(s)
IQR = interquartile range
MI = myocardial infarction
OCT = optical coherence
tomography
PCI = percutaneous coronary
intervention
RR = risk ratio
STEMI = ST-segment elevation
myocardial infarction
TIMI = Thrombolysis In
Myocardial Infarction
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960P rimary percutaneous coronary inter-vention (PCI) has been shown tosigniﬁcantly improve the survival of
patients with ST-segment elevation myocar-
dial infarction (STEMI) (1). Current STEMI
guidelines apply equally to both sexes
(2,3), although women have been under-
represented in randomized clinical trials of
primary PCI and sex differences in the pre-
sentation, pathophysiology, and treatment
of STEMI have been highlighted (4).
Clinical studies exploring sex diversity in
STEMI are limited by the confounding effect
of age at presentation (5,6). In addition, these
studies lack the ability to assess in vivo
characteristics and components of coronaryplaques underlying thrombosis (7). On the other
hand, autopsy series suggested a sex difference in the
morphology of plaques responsible for coronary
thrombosis (8), with plaque rupture, characterized by
disruption of a ﬁbrous cap over a necrotic core,
occurring more frequently in men dying of acute
myocardial infarction (9), and plaque erosion, char-
acterized by absence of communication between the
underlying plaque and coronary thrombus, being
more frequently observed in younger individuals and
women (10). Importantly, these observations are
limited by the inherent selection bias of post-mortem
investigations.
The effect of sex on vascular response to primary
PCI has also never been systematically investigated
in vivo. Women have smaller coronary vessels than
men do, and their biological response to vascular
damage worsens with aging and reduced exposure
to circulating estrogens (11,12). Whereas current-
generation everolimus-eluting stents (EES) have
shown reassuring outcomes in STEMI patients un-
dergoing primary PCI (13), there are no comparative
data between women and men on vascular healing
response to EES implanted in STEMI.s, and Boston Scientiﬁc. Dr. Sirbu has received grant support from
bbott Vascular, Terumo, and Volcano Corporation. Dr. Fineschi
eneca. Dr. Trani has received consulting fees from Esaote Biom
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t received April 9, 2014; accepted May 8, 2014.Optical coherence tomography (OCT) has been
recently validated as a highly reproducible intra-
coronary imaging technique that enables in vivo
characterization of culprit plaque features as well as
vascular response to stent implantation with close
correlation to histological ﬁndings (14,15).
This study was designed to characterize sex-related
differences in the pathophysiology of STEMI and
vascular healing response to primary PCI with current-
generation EES, after accounting for the confounding
effect of age. To this aim, a comprehensive investiga-
tion was undertaken with serial OCT, histopathology-
immunohistochemistry of thrombus aspirates, and
serum biomarkers.
METHODS
STUDY DESIGN. The OCTAVIA (Optical Coherence To-
mography Assessment of Gender Diversity in Primary
Angioplasty) study was a prospective, multicenter,
controlled trial involving patients with STEMI under-
going primary PCI. The study was promoted and sup-
ported by the Italian Society of Invasive Cardiology
with unrestricted grant support provided by Abbott
Vascular (Santa Clara, California). OCT catheters for
the study were donated by St. Jude Medical (St. Paul,
Minnesota). Neither company was involved with any
of the study processes, including site selection, data
collection, analysis, and drafting of the present paper.
The principal investigator had unrestricted data access
after the databasewas locked, sharedwith the Steering
Committee the decision to submit the results for
publication, and prepared the paper. The ethics com-
mittee in each participating center approved the
study, and all patients gave written informed consent.
STUDY POPULATION AND AGE MATCHING.
Consecutive patients $18 years of age who presented
within 6 h following the onset of symptoms, with
ST-segment elevation of $1 mm in at least 2 contig-
uous leads, new left bundle branch block, or trueSt. Jude Medical. Dr. Garbo has received consulting
serves on the Speakers’ Bureaus of St. Jude Medical
edica; and has received lecture fees from Abbott
ees from Medco, Abbott Vascular, Eli Lilly, Boston
rt and honoraria from St. Jude Medical and Abbott
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961posterior myocardial infarction (MI) were considered
for enrollment. Clinical exclusion criteria com-
prised cardiogenic shock, renal failure, recent major
bleeding, allergy to aspirin or clopidogrel, and
anticoagulant therapy. Clinically eligible patients
underwent coronary angiography and were enrolled
in the study if they fulﬁlled explicit angiographic
criteria. Detailed inclusion and exclusion criteria are
listed in the Online Appendix.
Matching of sex by age was performed with the use
of a computer-assisted, interactive voice response
system that selectively blocked the enrollment of
men or women to ensure recruitment of age-balanced
groups. This procedure was carried out during the
diagnostic phase of primary PCI and led to enrollment
only provided that age matching was fulﬁlled.
STUDY PROCEDURES AND FOLLOW-UP. In patients
presenting with TIMI (Thrombolysis In Myocardial
Infarction) ﬂow grades 2 to 3 in the infarct-related ar-
tery and no evidence of angiographic ﬁlling defect,
OCT was performed before any intervention.
Conversely, in case of TIMI ﬂow grades 0 to 1 or ﬁlling
defect, OCT was performed after manual thrombec-
tomy. No balloon pre-dilation was allowed before the
OCT pullback. All patients received EES (Xience Prime,
Abbott Vascular, Santa Clara, California). Adequacy of
stent placement and expansion were assessed based
on angiographic evaluation only. Aspirin 250 mg was
given intravenously before PCI, followed by 100 mg
oral aspirin daily indeﬁnitely thereafter. A loading
dose of clopidogrel (600 mg) or prasugrel (60 mg) was
administered before PCI followed by clopidogrel 75 mg
or prasugrel 10 mg daily for 12 months.
Clinical examinations were performed at 30 days, 9
months, and 1 year. Angiographic and OCT follow-up
at 9 months after stent implantation was electively
planned for all patients.
QUANTITAT IVE CORONARY ANGIOGRAPHY.
Quantitative coronary angiography was performed at
baseline, immediately after PCI, and at follow-up
in at least 2 orthogonal views after administration
of 200 mg intracoronary nitroglycerin. Digital coro-
nary angiograms were analyzed off-line at the
angiographic core laboratory (Cardiovascular Imaging
Core Laboratory, University Hospitals Case Medical
Center, Cleveland, Ohio) with a validated automated
edge detection system (CAAS II, PIE Medical, Maas-
tricht, the Netherlands) by operators blinded to
group assignment. The full quantitative coronary
angiography methodology is provided in the Online
Appendix.
OCT ASSESSMENT. Image acqu is i t ion and qua l i ty
screen ing . Images were acquired with a frequencydomain OCT system (C7-XRTM FD-OCT Intravascular
Imaging System, St. Jude Medical, St. Paul, Minne-
sota) at 3 time points: 1) after vessel patency
restoration (baseline); 2) after stent implantation
(post-procedural assessment); 3) at 9 months (follow-
up assessment). Raw OCT data were digitally stored,
deidentiﬁed, and submitted to an independent core
laboratory (Cardiovascular Imaging Core Laboratory)
for subsequent analyses. All cross-sectional images
were screened for quality and excluded from analysis
if any portion was out of the screen; if a side branch
occupied >45 of the cross section; or if the image
had poor quality caused by suboptimal blood clear-
ance, excessive residual thrombus, or artifacts (11). In
case of multiple pullbacks, integrated information
was obtained by using ﬁducial points (i.e., stent
edges, side branches). A dedicated software (OCT
system software B.0.1, LightLab, Westford, Massa-
chusetts) was used for quantiﬁcation. Qualitative
assessment was performed every 0.2 mm, whereas
quantitative and morphometric analyses were per-
formed every 0.6 mm along the entire target
segment. OCT analysis was performed by 2 indepen-
dent readers, blinded to the patient information and
sex, and by the same readers at 2 separate time
points, respectively. Interobserver reproducibility for
primary endpoints was assessed by calculating the
mean  SD of between-observer differences. The
kappa statistic was calculated as 0.845 (95% conﬁ-
dence interval [CI]: 0.769 to 0.921) (p < 0.001 to test
kappa statistic ¼ 0).
Basel ine et io logy assessment . OCT images were
analyzed using previously validated criteria for pla-
que characterization (15). Plaque rupture was deﬁned
as presence of ﬁbrous cap discontinuity and a cavity
formation in the underlying plaque beginning at the
luminal-intimal border. Plaque nonrupture/erosion
was deﬁned as the lack of evidence of a ﬁbrous cap
rupture at the culprit site, evaluated in multiple
adjacent frames, with evidence of an irregular
luminal surface. Spontaneous dissection was identi-
ﬁed as the presence of intima-medial ﬂap with mural
hematoma in a vessel with no or mild atherosclerotic
disease. Unclassiﬁed etiology was assigned when OCT
was unable to rule out the presence of plaque rupture
or erosion due to excess of residual thrombus
obscuring the underlying structures or in the pres-
ence of procedural intimal dissection induced by the
thrombectomy device. Intracoronary thrombus was
identiﬁed as an intraluminal mass with irregular
contour ﬂoating within the lumen or attached to the
intimal surface. In ruptured plaques, minimum
ﬁbrous cap thickness was measured at the thinnest
point of the remnant cap, whereas mean cap thickness
FIGURE 1 Study Enrollment
Of the 140 age-matched patients with ST-segment elevation myocardial
infarction (STEMI), 118 received manual thrombus aspiration. Of the 104
retrieved thrombi, 79 were analyzed (25 were excluded for insufﬁcient
material). All the patients underwent an optical coherence tomography (OCT)
pullback of the culprit vessel after thrombus aspiration, and 128 were suitable
for culprit lesion evaluation. All patients received OCT pullback after
stent implantation, and 139 of them were analyzable. Of the 140 patients,
134 were admitted at 9-month follow-up (6 of them died), 120 underwent
coronary angiography, and 117 OCT pullbacks were analyzed. All 134 patients
were admitted at 12-month follow-up. ES ¼ eluting stent(s).
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962was computed as the mean of 3 evenly distributed
measurements along the ﬁbrous cap. Fibrocalciﬁc
plaques were identiﬁed as well-delineated, signal-
poor regions with sharp borders; ﬁbrotic plaques as
homogeneous, signal-rich regions with low attenua-
tion; and lipid plaques as signal-poor regions with
high attenuation and diffused borders. When ﬁbro-
calciﬁc, ﬁbrotic, or lipid constituents were present
in $2 contiguous quadrants in any of the images
within a plaque, the cross section was classiﬁed
accordingly as ﬁbrocalciﬁc, ﬁbrous, or lipid rich.Post-procedura l and fo l low-up assessment .
For the morphometric analysis, standard deﬁnitions
of cross-sectional area and volume measurements
were applied as previously reported (12). Stent,
lumen, and neointimal hyperplasia cross-sectional
areas were measured at 0.6-mm axial increments
throughout the entire length of the stent, and
respective volumes were calculated according to the
Simpson rule. Proximal and distal references were
measured at the site with the largest lumen within
5 mm proximal and distal to the stented segment. The
minimum stent cross-sectional areas divided by the
average of proximal and distal reference lumen cross-
sectional areas ratio was calculated as a parameter of
stent expansion.
OCT stent analysis immediately post-procedure
and at follow-up was performed at the stent strut
level. Strut-lumen distance was determined based on
automated measurements performed from the center
of the strut blooming to the luminal contour of the
artery wall. Incomplete strut apposition was deﬁned
when this distance was higher than the sum of strut
thickness plus abluminal polymer thickness accord-
ing to stent manufacturer’s speciﬁcations plus a
compensation factor of 18 mm to correct for strut
blooming. Struts were “covered” if tissue could be
identiﬁed above the stent struts or “uncovered” if no
evidence of tissue could be imaged above the struts.
Percentage of covered and uncovered struts was
calculated as the number of struts with/without
distinct overlying tissue, in which the luminal
reﬂection of the strut surface was directly interfacing
with the lumen, divided by the total number of
analyzable struts.
HISTOPATHOLOGICAL ASSESSMENT OF THROMBUS.
Thrombus aspirate, if any, was collected and sent
to the independent histopathology core laboratory
(CV Path Institute, Gaithersburg, Maryland) for pro-
cessing. Aspirated thrombus tissues were wrapped in
ﬁlter paper and placed in tissue cassettes for histo-
logic processing. All sections were examined by light
microscopy for the presence of platelets, ﬁbrin, red
blood cells, plaque constituents, and inﬂammatory
cells. Additionally, immunohistochemical stains in-
cluding the granulocyte marker myeloperoxidase,
CD68 (macrophages), and the eosinophil marker
interleukin-5 were performed to further character-
ize speciﬁc inﬂammatory cell types. A CD42b stain
was used for the detection of platelets. Coronary
thrombus was classiﬁed into 2 stages of healing and
organization, as modiﬁcation of a previously reported
scoring system: stage 1 (early thrombus), composed of
alternating layers of platelets mixed with ﬁbrin and
TABLE 1 Baseline Demographic and Clinical Characteristics
Overall
(N ¼ 140)
Men
(n ¼ 70)
Women
(n ¼ 70) p Value
Age, yrs 66.6  11.1 65.3  11.8 67.8  10.4 0.19
Age group, yrs 1.00
#60 40/140 (28.5) 20/70 (28.5) 20/70 (28.5)
61–80 82/140 (58.6) 41/70 (58.6) 41/70 (58.6)
>80 18/140 (12.9) 9/70 (12.9) 9/70 (12.9)
Body mass index, kg/m2 26.0 (24.2, 29.1) 26.1 (24.2, 29.4) 25.5 (23.4, 29.1) 0.27
Body surface area, m2 1.8  0.2 2.0  0.2 1.7  0.2 <0.001
Hypertension 80/140 (57.1) 41/70 (58.6) 39/70 (55.7) 0.73
Hyperlipidemia 40/140 (28.6) 21/70 (30.0) 19/70 (27.1) 0.71
Current smoker 75/140 (53.6) 39/70 (55.7) 36/70 (51.4) 0.61
Diabetes 17/140 (12.1) 6/70 (8.6) 11/70 (15.7) 0.20
Previous MI 2/140 (1.4) 2/70 (2.9) 0/70 (0) 0.50
Previous PCI 2/140 (1.4) 1/70 (1.4) 1/70 (1.4) 1.00
Previous CABG 1/140 (0.7) 1/70 (1.4) 0/70 1.00
Time from symptom onset
to catheterization
laboratory, h
2.4 (1.7–3.5) 2.3 (1.6–3.1) 2.5 (1.8–4.0) 0.05
Killip class 0.79
I 125/140 (89.3) 63/70 (90.0) 62/70 (88.6)
II 15/140 (10.7) 7/70 (10.0) 8/70 (11.4)
Anemia* 15/140 (10.7) 7/70 (10.0) 8/70 (11.4) 0.79
TIMI risk score† 3 (2–5) 3 (1–4) 4 (2–5) 0.001
Values are mean  SD, n/N (%), or median (interquartile range). *Anemia was deﬁned, according to the WHO
criteria, as a hematocrit value at initial presentation of <39% for men and <36% for women. †TIMI risk score is
deﬁned considering the following variables: age, presence of diabetes, hypertension or angina, systolic heart
pressure <100 mm Hg, heart rate >100 beats/min, Killip class II to IV, weight <67 kg, presentation as anterior
STEMI or as left bundle branch block and time to treatment >4 h.
CABG ¼ coronary artery bypass graft; MI ¼ myocardial infarction; PCI ¼ percutaneous coronary intervention;
STEMI ¼ ST-segment elevation myocardial infarction; TIMI ¼ Thrombolysis In Myocardial Infarction; WHO ¼
World Health Organization.
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963neutrophils without evidence of cellular organiza-
tion; and stage 2 (organized thrombus), representing
a healing thrombus characterized by inﬁltration of
smooth muscle cells and/or endothelial cells with or
without proteoglycan matrix (16). The full histo-
pathological methodology is provided in the Online
Appendix.
SERUM BIOMARKERS ASSESSMENT. In all patients,
venous blood samples were drawn before coronary
angiography. After centrifugation, serum was stored
at –80C and sent to the core laboratory (Institute of
Cardiology, Catholic University of the Sacred Heart,
Roma, Italy). Analyses of serum comprised high-
sensitivity C-reactive protein, myeloperoxidase,
eosinophil cationic protein, and thromboxane B2.
Detailed methodology is described in the Online
Appendix.
STUDY ENDPOINTS. There were 2 pre-speciﬁed pri-
mary endpoints: 1) percentage of plaque rupture at
the infarct-related lesion; and 2) percentage of stent
strut coverage at 9 months after EES implantation.
Secondary endpoints included histopathology and
immunohistochemistry measurements of aspirated
thrombus specimens; measurements of blood bio-
markers collected at admission; the 9-month re-
sponse to EES implantation, assessed as percentage of
stent volume obstruction and percentage of incom-
plete strut apposition at OCT follow-up; and clinical
outcomes.
Major adverse cardiac or cerebrovascular events
(e.g., the composite of cardiac death, recurrent
MI, stroke, or ischemia-driven target lesion revascu-
larization), individual components of major adverse
cardiac or cerebrovascular events, target vessel re-
vascularization, and stent thrombosis were assessed
at 30 days, 9 months, and 1 year and adjudicated by
an independent clinical event committee after review
of original clinical data source. Target lesion revas-
cularization was considered to be ischemia-driven if
documented by a positive functional study or in the
presence of ischemic changes on an electrocardiogram
referable to the target lesion. Stent thrombosis was
deﬁned according to the Academic Research Con-
sortium (17).
STATISTICAL ANALYSIS. The study was designed to
evaluate whether culprit lesions in men with STEMI
have a different probability of having a ruptured
plaque morphology than those in women. Assuming a
plaque rupture rate of 82% in men and 60% in women
(9), with 1:1 assignment of 140 patients to the
2 groups, and 94% of the patients available for the
analysis, we calculated that the study would have80% power, with 0.05 alpha (2-sided), and a superi-
ority scope. The study was also powered to show the
noninferiority of EES strut coverage at 9 months
in women versus men. Assuming a noninferiority
margin of 2% and an SD of uncovered strut per-
centage of 4%, a similar 94.3% per-segment preva-
lence of uncovered struts in men and women,
and 80% of the patients available for the analysis at 9
months, a total sample size of 140 patients would
achieve 85% power and 0.05 alpha (1-sided), with a
noninferiority scope.
Patient, lesion, and procedural characteristics and
event rates were analyzed using descriptive statistics
with SAS (version 9.1 or higher, SAS Institute Inc.,
Cary, North Carolina), and SPSS (version 20.0, IBM,
Armonk, New York). Categorical data were reported
as simple proportions. Continuous data were reported
as mean  SD, or median (interquartile range [IQR])
depending on validity or lack of normality assump-
tions. Overall comparisons across groups were based
on unpaired Student t test for continuous variables
(or Mann-Whitney U and Kruskal-Wallis tests in cases
of signiﬁcant departures from normality
TABLE 2 Angiograph
Lesions treated, n
Infarct related artery
Left anterior descend
Left circumﬂex
Right coronary
Multivessel disease
Pre-procedural thromb
Use of aspiration cathe
Use of GP IIb/IIIa inhib
Radial access
Stents implanted
per patient, n
Total stent length
per patient, mm
Direct stenting
Maximum pressure
per lesion, atm
Maximum balloon
diameter, mm
Baseline TIMI ﬂow grad
0/1
2
3
Final TIMI ﬂow grade
0/1
2
3
Procedural success
Values are mean  SD, n/N
GP ¼ glycoprotein; othe
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Smirnov or Shapiro-Wilks tests) and chi-square or
Fisher exact test for categorical variables (with the
latter used when the expected cell count was <5). The
primary superiority endpoint was also reported as
risk ratio (RR) (95% CI). Given the violation of
normality assumption, noninferiority in strut
coverage was tested with bootstrap resampling
(10,000 samples) of the difference in medians be-
tween men and women. Statistical signiﬁcance was
set at the 0.05 level, 1-tailed for the strut coverage
noninferiority analyses, and 2-tailed for all other an-
alyses, including the etiology analyses, with p values
unadjusted for multiplicity reported throughout.
RESULTS
BASELINE CHARACTERISTICS AND PROCEDURAL
DATA. Between January 26, 2011 and January 19, 2012
140 STEMI patients (70 men and 70 women) were
enrolled at 14 centers. The study ﬂow is shown in
Figure 1. Baseline characteristics were similar in theic and Procedural Characteristics
Overall
(N ¼ 140)
Men
(n ¼ 70)
Women
(n ¼ 70) p Value
1.2  0.5 1.2  0.5 1.1  0.5 0.72
0.40
ing 62/140 (44.3) 27/70 (38.6) 35/70 (50.0)
11/140 (7.9) 6/70 (8.6) 5/70 (7.1)
67/140 (47.9) 37/70 (52.9) 30/70 (42.9)
62/140 (44.3) 34/70 (48.6) 28/70 (40.0) 0.47
us 120/140 (85.7) 62/70 (88.6) 58/70 (82.9) 0.33
ter 118/140 (84.3) 61/70 (87.1) 57/70 (81.4) 0.35
itor 51/140 (36.4) 31/70 (44.3) 20/70 (28.6) 0.05
82/140 (58.6) 47/70 (67.1) 35/70 (50.0) 0.04
1.4  0.6 1.3  0.5 1.4  0.7 0.15
23.0 (18.8–33.0) 23.0 (21.8–33.0) 23.0 (18.0–35.3) 0.38
88/140 (62.9) 44/70 (62.9) 44/70 (62.9) 1.00
18 (16–20) 18 (16–20) 18 (16–20) 0.91
3.25 (3.0–3.5) 3.5 (3.0–4.0) 3.0 (3.0–3.5) 0.008
e 0.45
83/140 (59.3) 43/70 (61.5) 40/70 (57.2)
44/140 (31.4) 19/70 (27.1) 25/70 (35.7)
13/140 (9.3) 8/70 (11.4) 5/70 (7.1)
0.47
0/140 (0) 0/70 (0) 0/70 (0)
8/140 (5.7) 5/70 (7.1) 3/70 (4.3)
132/140 (94.3) 65/70 (92.9) 67/70 (95.7)
128/140 (91.4) 63/70 (90.0) 65/70 (92.9) 0.76
(%), or median (interquartile range).
r abbreviations as in Table 1.2 groups (Table 1), with the exception of lower body
surface area (1.7  0.2 m2 vs. 2.0  0.2 m2, p < 0.001)
and higher TIMI risk score (median: 4 [IQR: 2 to 5]
vs. 3 [IQR: 1 to 4], p < 0.001) in women versus men.
Time from symptom onset to arrival in the catheter-
ization laboratory was shorter in men than in women
(median: 2.3 h [IQR: 1.6 to 3.1 h] vs. 2.5 h [IQR: 1.8
to 4.0 h], p ¼ 0.05).
A radial approach was more frequently used in men
(67.1% vs. 50.0%, p ¼ 0.04), who were also more
likely to receive glycoprotein IIb/IIIa inhibitors
(44.3% vs. 28.6%, p ¼ 0.05) than women were. A total
of 120 patients (86%) had angiographic evidence of
thrombus, of which 118 underwent thrombus aspira-
tion, with no difference between men and women.
Angiographic, OCT, and procedural characteristics are
shown in Tables 2 and 3. Additional quantitative cor-
onary angiography measures are reported in Online
Table 1. Women had smaller vessels and accordingly
were treated with smaller balloons (median: 3.0 mm
[IQR: 3.0 to 3.5 mm] vs. 3.5 mm [IQR: 3.0 to 4.0 mm];
p ¼ 0.008) (Table 2) and smaller stents (OCT mini-
mum stent area 5.5  1.9 mm2 vs. 7.1  2.3 mm2; p <
0.001) (Table 3). Nevertheless, the stent expansion
index at implantation was similar between women
and men (85% vs. 87%; p ¼ 0.53), as were the residual
minimum lumen area stenosis (15.3% vs. 11.1%; p ¼
0.21) and the rate of acute incomplete stent strut
apposition (5.0% vs. 5.1%; p ¼ 0.99) (Table 3). The
prevalence of ﬁnal TIMI ﬂow grade 3 was similar in
the 2 groups (95.7% vs. 92.9%; p ¼ 0.72).
CULPRIT LESION ASSESSMENT. Baseline OCT images
of the culprit lesion were qualiﬁed for the etiology
analysis in 128 patients (91%). Thirty-one of 128
culprit lesions (24%) qualifying for the etiology
analysis were not classiﬁable by OCT, essentially
due to the excessive amount of remaining thrombus.
No differences in baseline and procedural character-
istics were observed between patients with classiﬁed
versus unclassiﬁed culprit plaques (Online Table 2)
except for the rate of thrombus at presentation (81.4%
vs. 96.8%; p ¼ 0.04). The primary endpoint, per-
centage of plaque rupture at the culprit coronary site,
was similar in men and women (50.0% vs. 48.4%; RR:
1.03, 95% CI: 0.73 to 1.47; p ¼ 0.56 for superiority)
(Figure 2). No sex differences were found at the
rupture plaque site in terms of minimum cap thick-
ness, length of plaque rupture, or plaque constituents
(all p > 0.05) (Table 3). Nonruptured/eroded plaques
comprised 25% of all cases, with similar distribution
in men and women (p ¼ 0.86).
STRUT COVERAGE AND VASCULAR RESPONSE AT
9 MONTHS. At 9 months, a similar total number of
TABLE 3 OCT Findings at Baseline and 9-Month Follow-Up
Culprit Lesion Assessment
Overall
(N ¼ 140)
Men
(n ¼ 70)
Women
(n ¼ 70) p Value
Residual thrombus 120/128 (93.8) 62/64 (96.9) 58/64 (90.6) 0.27
Rupture site assessment
Minimum cap thickness, mm 47  12 48  15 46  8 0.59
Mean cap thickness, mm 64  15 66  17 61  12 0.28
Length of plaque rupture, mm 1.8 (1.2–3.0) 1.8 (1.2–3.0) 1.8 (1.2–3.0) 0.80
Plaque constituents, %
Fibrocalciﬁc 4.6  12.7 4.5  13.7 4.6  11.9 0.74
Fibrous 14.8  17.0 13.0  16.4 16.8  17.6 0.32
Lipid-rich 74.5  20.0 79.2  24.0 69.8  23.5 0.09
Normal 6.0  12.0 3.3  8.8 8.8  14.2 0.10
Nonrupture/erosion site assessment
Plaque constituents, %
Fibrocalciﬁc 10.2  20.9 14.1  25.8 6.3  14.4 0.40
Fibrous 25.0  31.8 14.1  27.3 35.9  32.9 0.03
Lipid-rich 56.3  36.5 60.9  38.7 51.6  34.7 0.36
Normal 8.6  21.6 10.9  27.3 6.3  14.4 0.96
Post-Stent Implantation (N [ 139) (n [ 70) (n [ 69)
Mean reference vessel area, mm2 6.9 (5.5–9.7) 8.5 (6.2–10.7) 6.3 (5.1–8.3) <0.001
Minimum stent area, mm2 6.3  2.2 7.1  2.3 5.5  1.9 <0.001
Minimum lumen area, mm2 5.8 (4.5–7.6) 6.8 (5.2–8.6) 5.2 (4.4–6.3) <0.001
Minimum lumen area stenosis, % 13.2  19.9 11.1  20.5 15.3  19.2 0.22
Stent expansion index, %* 86 (70–96) 87 (69–100) 85 (71–96) 0.53
Incomplete strut apposition, %† 5.1 (1.5–10.6) 5.1 (1.5–10.8) 5.0 (1.7–10.5) 1.00
Follow-Up (N [ 117) (n [ 58) (n [ 59)
Mean reference vessel area, mm2 6.6 (5.1–8.9) 7.4 (5.7–10.5) 5.9 (4.3–7.8) 0.001
Minimum lumen area, mm2 5.18 (3.7–6.9) 5.9 (4.3–7.4) 5.0 (3.6–5.8) 0.01
Percentage net volume
obstruction, %
10.3 (6.0–15.8) 10.6 (6.7–16.1) 10.3 (5.9–13.7) 0.76
Incomplete strut apposition, %† 0.6 (0.0–4.8) 0.9 (0.0–6.4) 0.3 (0.0–3.5) 0.13
Values are n/N (%), mean  SD, or median (interquartile range). *Stent expansion index refers to minimum stent
area/reference lumen area. †Incomplete struts apposition percentage has been estimated only when applicable.
OCT ¼ optical coherence tomography.
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965struts were analyzed in both groups (total 10,147,
median 169 struts [IQR: 129 to 225 struts] in men,
and total 10,459, median 162 [IQR: 118 to 214 struts]
in women; p ¼ 0.30). The coprimary endpoint,
percentage of covered EES struts, did not differ
between men and women (92.5% [IQR: 83.7% to
97.5%] vs. 90.9% [IQR: 81.4% to 97.9%]; difference
in medians: 0.2% [95% CI: –0.4% to 1.3%]; p < 0.001
for noninferiority). No sex differences were noted
in the percentage of incomplete strut apposition
(0.9% [95% CI: 0.0 to 6.4] vs. 0.3% [95% CI: 0.0 to
3.5]; p ¼ 0.13) and in-stent volume obstruction
(10.6% [95% CI: 6.7 to 16.1] vs. 10.3% [5.9 to 13.7];
p ¼ 0.76).
HISTOPATHOLOGY, IMMUNOHISTOCHEMISTRY, AND
BIOMARKER ANALYSES. A total of 104 samples were
retrieved in ﬁlters. Seventy-nine specimens (40 from
men and 39 from women) were suitable for pathologic
analysis, whereas 25 samples were excluded for
insufﬁcient material collection (Figure 1). Qualitative
histological analysis showed ﬁbrin and platelet-rich
thrombi with inﬂammatory cells, predominantly
neutrophils in both groups (Table 4). All histologic
and immunohistochemistry ﬁndings were similar in
men and women. Assessment of serum biomarkers at
the time of admission showed similar values in the
2 groups for C-reactive protein, myeloperoxidase,
eosinophil cationic protein, and thromboxane B2 (all
p > 0.05) (Table 4).
CLINICAL OUTCOMES. In-hospital, 1-month, and
1-year adverse events occurred with similar fre-
quency in men and women (Table 5). The 2 study
groups received similar therapies and showed similar
compliance over time (Online Table 3).DISCUSSION
We reported on the ﬁrst prospective controlled study
designed to assess in vivo sex differences in the
mechanisms of STEMI and vascular response to pri-
mary PCI with current-generation drug-eluting
stents. The main ﬁndings are that men and women
with STEMI, when matched for age, shared similar
plaque morphology, cellular composition, and
immunohistochemistry of thrombus, as well as
biomarker substrates. Moreover, the immediate- and
long-term vascular response to EES implantation was
similar in both sexes.
Autopsy studies have suggested differences in
morphology of the underlying plaque associated with
acute MI in women versus men (8–10). Although
plaque rupture of a thin-cap ﬁbroatheroma hasbeen recognized as the most prevalent pathologic
substrate of STEMI, coronary thrombosis arising from
nonruptured/eroded plaques was frequently re-
ported, especially in women and young individuals.
However, no systematic investigation in vivo of
sex differences in culprit lesions phenotypes in
the setting of STEMI is currently available. In accor-
dance with previous post-mortem investigations,
we found ruptured plaques to be the most frequent
cause of coronary thrombosis, with approximately
two-thirds of the classiﬁed culprit lesions being
ruptured atherosclerotic plaques with thrombus,
and the remaining one-third being represented by
nonruptured/eroded plaques (Figure 2). Differently
from previous reports, however, our study showed
no sex gap in the prevalence of ruptured and
eroded plaques. A possible explanation for this
ﬁnding is that the age-matching algorithm might
FIGURE 2 Study Endpoints
Nature of culprit plaque underlying coronary thrombosis (index procedure) and vascular healing response to everolimus-eluting stent (9-month follow-up)
stratiﬁed by sex.
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966have signiﬁcantly reduced the differences in clinical
risk proﬁle between sexes. Indeed, modiﬁable
risk factors have been shown to account for 90%
of MI in both sexes (18) and are clearly linked to
different plaque morphologies in patients with cor-
onary thrombosis (19,20). Moreover, in this study,
very few women <50 years of age, a group with
known higher prevalence of plaque erosion, were
included (21).
We found similar cellular composition and immu-
nohistochemistry of thrombus aspirates between
men and women, along with comparable levels of
systemic biomarkers of inﬂammation, immune
response, and platelet activation. These ﬁndings
support the validity of OCT imaging results for culprit
plaque morphology. Notably, one-third of the pa-
tients had evidence of thrombus organization despite
restricting enrollment only to patients within 6 h
from symptom onset, in keeping with previous ob-
servations (16).
The coprimary objective of our trial was to inves-
tigate whether there are sex-related differences in
vascular response to drug-eluting stents in the
setting of STEMI. The relevance of this problem has
been highlighted by the U.S. Food and Drug Admin-
istration, which issued a statement recommending
the analysis of sex-speciﬁc outcomes in trials withnovel implantable medical devices (22). Despite
ﬁnding that women have signiﬁcantly smaller coro-
nary vessels, all measured OCT and angiographic
parameters of stent performance and vascular re-
sponse were similar between men and women.
Speciﬁcally, rates of covered, uncovered, and in-
completely apposed struts were remarkably similar,
as was the percentage of in-stent lumen obstruction
and binary restenosis.
The potential for a different outcome in women
after STEMI has been described for many years (23).
In our study, where patients and treatment strategies
were comparable between sexes, 30-day and 1-year
outcomes were similar. These ﬁndings suggest that
disparities in age, risk factors, timing of presenta-
tion, and management rather than different biologi-
cal mechanisms and response to treatment might
be more relevant in affecting clinical outcome
(24). However, the study was not powered to detect
differences in clinical outcomes, and therefore, this
result must be interpreted with caution.
STUDY LIMITATIONS. First, the entry criteria limited
the enrollment to a low-risk, selected population.
This was necessary to perform all of the study-
required evaluations, including multiple OCT pull-
backs. Second, the core laboratory was unable to
classify the culprit plaque in one-quarter of the cases,
TABLE 5 Clinical Outcomes at 30 Days and 1 Year
Overall Men Women p Value
30 days
MACCE 5/140 (3.6) 4/70 (5.7) 1/70 (1.4) 0.37
Death 2/140 (1.4) 1/70 (1.4) 1/70 (1.4) 1.00
Cardiac 2/140 (0.7) 1/70 (0.0) 1/70 (1.4) 1.00
Noncardiac 0/140 (0.7) 0/70 (1.4) 0/70 (0.0) 1.00
Reinfarction 2/140 (1.4) 2/70 (2.9) 0/70 (0.0) 0.50
Stroke 1/140 (0.7) 1/70 (1.4) 0/70 (0.0) 1.00
Stent thrombosis 3/140 (2.1) 2/70 (2.9) 1/70 (1.4) 1.00
Deﬁnite 2/140 (1.4) 2/70 (2.9) 0/70 (0.0) 0.50
Probable 1/140 (0.7) 0/70 (0.0) 1/70 (1.4) 1.00
Ischemia-driven target
lesion revascularization*
2/140 (1.4) 2/70 (2.9) 0/70 (0.0) 0.50
Target vessel revascularization 2/140 (1.4) 2/70 (2.9) 0/70 (0.0) 0.50
1 year†
MACCE 9/140 (6.4) 5/70 (7.1) 4/70 (5.7) 0.69
Death 6/140 (4.3) 3/70 (4.3) 3/70 (4.3) 1.00
Cardiac 3/140 (1.4) 1/70 (1.4) 2/70 (2.9) 0.57
Noncardiac 3/140 (2.9) 2/70 (2.9) 1/70 (1.4) 0.56
Reinfarction 2/140 (1.4) 2/70 (2.9) 0/70 (0.0) 0.16
Stroke 1/140 (0.7) 1/70 (1.4) 0/70 (0.0) 0.31
Stent thrombosis 3/140 (2.1) 2/70 (2.9) 1/70 (1.4) 0.55
Deﬁnite 2/140 (1.4) 2/70 (2.9) 0/70 (0.0) 0.16
Probable 1/140 (0.7) 0/70 (0.0) 1/70 (1.4) 0.32
Ischemia-driven target
lesion revascularization*
5/140 (3.6) 3/70 (4.3) 2/70 (2.9) 0.69
Target vessel revascularization 9/140 (6.4) 5/70 (7.1) 4/70 (5.7) 0.72
Values are n/N (%). *Ischemia-driven target lesion revascularization refers to a procedure to treat recurrent
ischemia occurring within or just outside the stent. †The p values are based on the log-rank test.
MACCE ¼ major adverse cerebral and cardiovascular events (a composite of cardiac death, reinfarction, stroke,
and target lesion revascularization for ischemia, in hierarchical order).
TABLE 4 Histologic Assessment of Aspirated Thrombus and Inﬂammatory/Platelet Activation Biomarkers
Overall Men Women p Value
Aspirated thrombus, n 79 40 39
Thrombus volume, mm3 6 (3–15) 6 (3–18) 6 (2–15) 0.70
Platelets presence 79/79 (100) 40/40 (100) 39/39 (100) 1.00
Average WBC, cells/5HPF 75 (50–150) 75 (50–200) 75 (50–150) 0.22
Plaque material 40/79 (50.6) 20/40 (50.0) 20/39 (51.2) 0.91
Thrombus age 1.00
Early 56 (70.9) 28 (70.0) 28 (69.8)
Organized 23 (29.1) 12 (30.0) 11 (28.2)
Immunohistochemistry analysis
MPO, cells/5HPF 39 (26–90) 38 (24–86) 41 (26–91) 0.93
CD68, cells/5HPF 20 (10–40) 20 (10–50) 20 (10–30) 0.73
Interleukin-5, cells/5 HPF 0 (0–1) 0 (0–1) 0 (0–1) 0.93
CD42B score* 2 (2–3) 2 (2–3) 2 (2–3) 0.18
Blood biomarkers, n 129 65 64
CRP, mg/l 2.08 (1.00–4.11) 1.64 (0.88–4.77) 2.21 (1.01–4.02) 0.49
MPO, ng/ml 604.2 (290.5–1,496.9) 512.7 (271.4–1,308.7) 956.7 (303.7–1,658.7) 0.09
ECP, mg/l 5.0 (2.8–9.1) 5.1 (2.5–10.5) 4.5 (2.9–7.9) 0.65
TBX2, pg/ml 117.2 (60.6–256.1) 117.2 (58.5–189.1) 117.3 (62.9–261.6) 0.63
Values are median (interquartile range), n/N (%), or n (%). *The CD42B score employed a scale of 0 to 3 where 0 ¼ no platelets, 1# one-third of the thrombus area, 2# one- to
two-thirds of the thrombus area, and 3 $ two-thirds of the thrombus area.
5HPF ¼ 5 high-power ﬁeld; CRP ¼ C-reactive protein; ECP ¼ eosinophil cationic protein; MPO ¼ myeloperoxidase; TBX2 ¼ thromboxane-B2; WBC ¼ white blood cells.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 7 , N O . 9 , 2 0 1 4 Guagliumi et al.
S E P T E M B E R 2 0 1 4 : 9 5 8 – 6 8 Sex Differences in Acute Myocardial Infarction
967which is consistent with the latest OCT investigations
revealing signiﬁcant residual thrombus after throm-
bectomy, undetected by angiography (25,26). This
potential bias might be mitigated by the equal dis-
tribution of unclassiﬁable plaques in both sexes and
the similar clinical characteristics of patients with
classiﬁed or nonclassiﬁed plaques. Third, manual
thrombectomy was used in patients with TIMI ﬂow
grade 0/1 to recanalize the vessel and allow for
a safer and diagnostic OCT pullback. A role of the
thromboaspiration catheter in modifying the plaque
etiology when crossing the culprit lesion cannot be
entirely ruled out; however, it is likely that this ef-
fect, if any, was equally distributed in men and
women. Fourth, whereas OCT criteria for plaque
rupture are largely accepted, less explicit criteria
apply for nonruptured/eroded plaques (12). Fifth, the
study was not powered for clinical endpoints.
Finally, although age matching controlled a propor-
tion of baseline differences between men and
women, a role for residual confounding factors
cannot be excluded.
CONCLUSIONS
The present study shows that in age-matched men
and women presenting with STEMI, there are no
evident differences in culprit plaque morphology
and local or systemic factors associated with acute
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968coronary thrombosis. A favorable vascular response
to EES implantation with similar high rates of
complete stent strut coverage is observed in both
sexes.
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